GLP-1s

Patient safety groups are warning that an FDA advisory committee’s decision to recommend expanding compounding access to wellness peptides came without the safety and efficacy evidence needed to justify it. The FDA’s Pharmacy Compounding Advisory Committee voted during its July…

A new fracture-risk finding is complicating the bone-safety picture for GLP-1s, alongside fresh data on hair loss, sick leave and adherence.  Here are six recent findings to know:

The FDA’s Pharmacy Compounding Advisory Committee wrapped a two-day meeting July 24, ultimately recommending six of the seven peptides under review — BPC-157, KPV, TB-500, MOTs-C, epitalon and Semax — for inclusion on the agency’s Section 503A Bulk Drug Substances…

GLP-1 receptor agonists carry a higher risk of hair loss than other diabetes medications, according to a study published July 22 in The BMJ. Researchers at Philadelphia-based Penn Medicine used EHR data to compare adults with Type 2 diabetes who…

A research letter published online July 20 in JAMA Pediatrics examined obesity treatment trends among adolescents and young adults between May 2022 and January 2026.  Here are four findings to know: The shift builds on trends already showing up in…

Some compounding pharmacies are sidestepping the FDA’s ban on copying approved GLP-1s by adding a vitamin or supplement to their formulations, according to a report published July 17 in JAMA Health Forum. The finding is a sign that the legal…

GLP-1 medications are linked to a 17.3% drop in long-term sickness leave over four years, according to a working paper published in July by the National Bureau of Economic Research. Researchers compared 7,011 patients who started Ozempic during the drug’s…

Some compounding pharmacies are making slight tweaks to the composition of their GLP-1s to sidestep an FDA ban on copying approved semaglutide and tirzepatide products, suggest the findings of a study published July 17 in JAMA Health Forum. Surging demand…

Connecticut has paused plans to seek federal approval to partner with a generic drug manufacturer to lower the cost of GLP-1 medications, despite a state law requiring the effort, according to a July 16 report from the CT Mirror. Gov.…

Average total payments for GLP-1 users without diabetes rose sharply between 2017 and 2022, even as patients personally paid less out of pocket, according to a Northwestern University study published July 16 in the Journal of the American Heart Association. …